報價延遲最少15分鐘:2024/05/31 22:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.38 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.93/-1.86
|
|
企業價值
355.76M
|
| 資產負債 |
|
每股賬面淨值
2.71
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.66M
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/31 22:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. |